FINWIRES · TerminalLIVE
FINWIRES

AdaptHealth's Labor Headwinds Lead to Fast Onboarding of Capitated Contract, RBC Says

By

AdaptHealth's (AHCO) increased spending on labor that weighed on its Q1 results ensured the "smooth" rollout of a major capitated contract in the home medical equipment space, RBC Capital Markets said in a note Friday.

AdaptHealth is now well positioned to extend the relationship beyond the initial five-year period, while the new contract serves as a proof of concept that could attract additional large-scale capitated partners, the investment firm said.

Management said the $12 million labor headwind includes $8 million variable labor cost to boost the capitated go-live process and $4 million of temporarily high wages and benefits from "duplicative regional onboarding," the note said.

The $8 million variable labor cost is likely to normalize by the end of Q2, while the $4 million will likely decrease as the operating model right-sizes, RBC said.

RBC kept AdaptHealth's outperform rating and increased the price target to $15 from $13.

Shares of AdaptHealth were up 0.7% in Monday trading.

Price: $11.38, Change: $+0.07, Percent Change: +0.66%

Related Articles

Australia

Truist Securities Lifts NETSTREIT Price Target to $22 From $21, Maintains Buy Rating

NETSTREIT (NTST) has an average rating of overweight and mean price target of $21.97, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $20.73, Change: $+0.06, Percent Change: +0.29%

$NTST
Australia

Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says

Gilead Sciences' (GILD) mid-stage trial results from its ulcerative colitis drug candidate, emvistegrast, are not expected to move the stock, RBC Capital Markets said in a note Monday.The outcome from the small molecule drug trial is expected shortly, the note said, adding that the competitive bar is high, and prior oral efforts have not looked great."Focus is likely to remain on Yeztugo/HIV/anito-cel nearterm, and a ph. II readout is unlikely to materially move the stock," the report said.The note said the drug candidate has some pharmacological advantages against others and favorable results could help its immunology and inflammation segment emerge as a potential new area of long-term growth generation.The report pointed to Eli Lilly's (LLY) recent EMERALD-2 phase 2b data that showed only modest efficacy.RBC kept its sector perform rating with a price target of $122.Price: $133.64, Change: $+2.31, Percent Change: +1.76%

$GILD
Australia

Argus Adjusts Price Target on Targa Resources to $290 From $270

Targa Resources (TRGP) has an average rating of overweight and mean price target of $271.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $254.86, Change: $+6.74, Percent Change: +2.72%

$TRGP